A positive correlation between YAP/TAZ levels and cancer malignancy (including lower response to therapy), or a higher YAP/TAZ expression level compared to normal tissue, has been observed in several human cancer or murine models, including colorectal, liver, lung, pancreatic, gastric, and breast cancer (see [51] for a review). This evidence concerns the gene YAP1 and cancer.